Anatomic Stage I Breast Cancer AJCC v8Phase 3NCT04379570
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
A Phase 3 study testing Educational Intervention, Text Message-based Navigation Intervention and Motivational Interviewing in people with Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, run by Alliance for Clinical Trials in Oncology at 526 sites in United States.
Trial summary
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- What is being tested?
- Educational Intervention, Text Message-based Navigation Intervention and Motivational Interviewing
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,167 participants
- Where
- 526 sitesUnited States
- Study dates
- 15 Feb 2021to 4 Oct 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
- Women with an initial pathologically confirmed diagnosis of stage I-III, hormone receptor positive, HER2-neu negative, invasive breast cancer within 18 months (>=548 days) prior to registration.
- If a patient has undergone neo-adjuvant chemotherapy and had no residual invasive disease at the time of surgery, eligibility can be based on a clinical stage I-III prior to treatment and pathologic confirmation of receptor status from a diagnostic biopsy.
- Hormone receptor positive is defined as estrogen receptor (ER) and/or progesterone receptor (PR) or both of > 1%
- HER2-neu negative is defined as 0-1+ by immunohistochemical (IHC) analysis, or non-amplified by fluorescence in situ hybridization (FISH) analysis. If HER2-neu status is unknown due to insufficient tissue for evaluation, the patient is eligible
- Patients with synchronous primary tumor foci of different receptor phenotypes, whether in the same or contralateral breast, may be enrolled as long as one tumor focus meets the receptor criteria and the patient is otherwise eligible
Prior Treatment:
- Patients must have completed all planned cancer-directed surgery (except reconstruction surgery or oophorectomy)
- Patients must have completed all other adjuvant therapy (e.g., radiation and intravenous [IV] or oral chemotherapy) prior to registration
- Patients who will be taking a CDK4/6 inhibitor (e.g., abemaciclib, palbociclib, or ribociclib) during endocrine therapy are NOT permitted to enroll as this is considered ongoing adjuvant therapy
- Patients who have previously been on ET drug outside the 6-month window for any reason, including breast cancer prevention or high-risk non-malignant lesions (e.g., atypical ductal hyperplasia [ADH], lobular carcinoma in situ [LCIS]) are ineligible
- Patients must be taking a once daily endocrine therapy drug initiated within the 6 months prior to registration, OR have received a prescription for a once daily ET medication with stated intent to initiate within 6 weeks after registration.
- Patients who switch ET drugs prior to enrollment remain eligible as long as the total time since initiation of the first ET drug does not exceed 6 months prior to registration
- Patients who have stopped their ET drug prior to enrollment and not started another ET drug are ineligible
- No history of previous cancer as follows:
- Invasive or non-invasive breast cancer at any time
- Non-breast cancer, within the past 5 years, excluding non-melanoma skin cancer
- Patients with a history of high-risk breast lesions (e.g., atypical ductal hyperplasia - ADH, lobular carcinoma in situ - LCIS are eligible as long as they have not previously taken an endocrine therapy drug
- Patients must be willing to use a smart phone for study activities
- Patient is NOT to be deemed ineligible during the recruitment process if they do not have a smart phone
- A smart phone and service can be provided to the participant at no cost for the duration of the study activities if the participant meets at least one of the following criteria: (1) does not own a smart phone or (2) has limited data, minutes or texting plan or (3) their smart phone cannot support the Alliance electronic patient reported outcomes (ePRO) survey app. Study provided smart phones will be provided through the Ohio State University (OSU) partnership with Verizon Wireless.
- The CRP is ONLY to discuss this option with those patients who self-identify a phone-related barrier to participation, including: lack of a smart phone, insufficient phone plan (minutes/text/data), or a smart phone incompatible with the Alliance ePRO app
- Patients must be willing to use the AdhereTech medication electronic pill cap for the duration of study participation
- Patients must be willing to use the study-provided electronic pill cap as a medication event monitoring system each time ET drug is taken. Use of any other container (e.g., pill box, etc.) for ET drug during study period is not permitted
- Age >= 18 years
- In order to complete the mandatory patient-completed measures, participants must be able to speak and read English
- Co-enrollment is allowed with the permission of the Alliance Executive Officer and both studies' Study Chairs
Trial locations and contacts
526 sites in 1 country.
300 sites in 1 country
United States300 sites
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii, 96701
UM Upper Chesapeake Hematology and Oncology - Aberdeen
Aberdeen, Maryland, 21001
Summa Health System - Akron Campus
Akron, Ohio, 44304
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota, 56007
Presbyterian Kaseman Hospital
Albuquerque, New Mexico, 87110
Aultman Alliance Community Hospital
Alliance, Ohio, 44601
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, 79106
Mary Greeley Medical Center
Ames, Iowa, 50010
McFarland Clinic - Ames
Ames, Iowa, 50010
Community Hospital of Anaconda
Anaconda, Montana, 59711
Kaiser Permanente-Anaheim
Anaheim, California, 92806
AnMed Health Cancer Center
Anderson, South Carolina, 29621
UTMB Health Angleton Danbury Campus
Angleton, Texas, 77515
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, 48106
Luminis Health Anne Arundel Medical Center
Annapolis, Maryland, 21401
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
Kaiser Permanente-Deer Valley Medical Center
Antioch, California, 94531
Ascension Saint Elizabeth Hospital
Appleton, Wisconsin, 54915
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California, 93420
AdventHealth Infusion Center Asheville
Asheville, North Carolina, 28803
Duluth Clinic Ashland
Ashland, Wisconsin, 54806
Sutter Auburn Faith Hospital
Auburn, California, 95602
Hematology Oncology Associates of Central New York-Auburn
Auburn, New York, 13021
MultiCare Auburn Medical Center
Auburn, Washington, 98001
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
Rush-Copley Medical Center
Aurora, Illinois, 60504
Saint Alphonsus Cancer Care Center-Baker City
Baker City, Oregon, 97814
Kaiser Permanente-Baldwin Park
Baldwin Park, California, 91706
Mercy Oncology and Hematology - Clayton-Clarkson
Ballwin, Missouri, 63011
Mercy Medical Center
Baltimore, Maryland, 21202
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Summa Health System - Barberton Campus
Barberton, Ohio, 44203
Advocate Good Shepherd Hospital
Barrington, Illinois, 60010
Bronson Battle Creek
Battle Creek, Michigan, 49017
Baptist Hospitals of Southeast Texas Cancer Center
Beaumont, Texas, 77701
Indu and Raj Soin Medical Center
Beavercreek, Ohio, 45431
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Kaiser Permanente-Bellflower
Bellflower, California, 90706
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Saint Charles Health System
Bend, Oregon, 97701
UCSF Cancer Center - Berkeley
Berkeley, California, 94702
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Walter Reed National Military Medical Center
Bethesda, Maryland, 20889-5600
Beverly Hospital
Beverly, Massachusetts, 01915
Billings Clinic Cancer Center
Billings, Montana, 59101
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Saint Elizabeth Boardman Hospital
Boardman, Ohio, 44512
Prisma Health Cancer Institute - Spartanburg
Boiling Springs, South Carolina, 29316
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
McFarland Clinic - Boone
Boone, Iowa, 50036
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Bozeman Health Deaconess Hospital
Bozeman, Montana, 59715
Essentia Health Saint Joseph's Medical Center
Brainerd, Minnesota, 56401
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan, 48114
Trinity Health Medical Center - Brighton
Brighton, Michigan, 48114
Bristol Regional Medical Center
Bristol, Tennessee, 37620
Ballad Health Cancer Care - Bristol
Bristol, Virginia, 24201
Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Brookfield, Wisconsin, 53045
Maimonides Medical Center
Brooklyn, New York, 11219
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin, 53105
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Minnesota Oncology - Burnsville
Burnsville, Minnesota, 55337
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, 83605
Cambridge Medical Center
Cambridge, Minnesota, 55008
Hematology Oncology Associates of CNY at Camillus
Camillus, New York, 13031
Illinois CancerCare-Canton
Canton, Illinois, 61520
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan, 48188
Trinity Health Medical Center - Canton
Canton, Michigan, 48188
Aultman Health Foundation
Canton, Ohio, 44710
Mercy Cancer Center - Cape Girardeau
Cape Girardeau, Missouri, 63703
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
SIH Cancer Institute
Carterville, Illinois, 62918
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Waverly Hematology Oncology
Cary, North Carolina, 27518
Physicians' Clinic of Iowa PC
Cedar Rapids, Iowa, 52402
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Rocky Mountain Cancer Centers - Centennial
Centennial, Colorado, 80112
Dayton Physicians LLC-Miami Valley South
Centerville, Ohio, 45459
Miami Valley Hospital South
Centerville, Ohio, 45459
Centralia Oncology Clinic
Centralia, Illinois, 62801
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599
Chelsea Hospital
Chelsea, Michigan, 48118
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan, 48118
Cancer Specialists of Tidewater Limited
Chesapeake, Virginia, 23320
Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Enloe Medical Center
Chico, California, 95926
Adventist Health Cancer Care Center Chico
Chico, California, 95973
Ascension Calumet Hospital
Chilton, Wisconsin, 53014
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
Oncology Hematology Care Inc-Kenwood
Cincinnati, Ohio, 45236
Providence Cancer Institute Clackamas Clinic
Clackamas, Oregon, 97015
Newland Medical Associates-Clarkston
Clarkston, Michigan, 48346
MetroHealth Medical Center
Cleveland, Ohio, 44109
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
AdventHealth Infusion Center Haywood
Clyde, North Carolina, 28721
Billings Clinic-Cody
Cody, Wyoming, 82414
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Main Line Health Center-Collegeville
Collegeville, Pennsylvania, 19426
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia, Missouri, 65212
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Cookeville Regional Medical Center
Cookeville, Tennessee, 38501
Mercy Hospital
Coon Rapids, Minnesota, 55433
AMG Crystal Lake - Oncology
Crystal Lake, Illinois, 60014
Danbury Hospital
Danbury, Connecticut, 06810
Carle at The Riverfront
Danville, Illinois, 61832
MercyOne Genesis Davenport Medical Center
Davenport, Iowa, 52803
MercyOne Genesis Davenport Cancer Center
Davenport, Iowa, 52804
Iowa Cancer Specialists
Davenport, Iowa, 52807
Miami Valley Hospital
Dayton, Ohio, 45409
Dayton Physician LLC - Englewood
Dayton, Ohio, 45415
Miami Valley Hospital North
Dayton, Ohio, 45415
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Essentia Health - Deer River Clinic
Deer River, Minnesota, 56636
Broward Health North
Deerfield Beach, Florida, 33064
Kaiser Permanente-Franklin
Denver, Colorado, 80205
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa, 50309
Broadlawns Medical Center
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Essentia Health Saint Mary's - Detroit Lakes Clinic
Detroit Lakes, Minnesota, 56501
Illinois CancerCare-Dixon
Dixon, Illinois, 61021
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Advocate Good Samaritan Hospital
Downers Grove, Illinois, 60515
Kaiser Permanente Dublin
Dublin, California, 94568
Columbus Oncology and Hematology Associates
Dublin, Ohio, 43016
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Prisma Health Cancer Institute - Easley
Easley, South Carolina, 29640
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
HSHS Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Advocate Sherman Hospital
Elgin, Illinois, 60123
Walter Knox Memorial Hospital
Emmett, Idaho, 83617
Mountain Blue Cancer Care Center - Swedish
Englewood, Colorado, 80113
Rocky Mountain Cancer Centers - Swedish
Englewood, Colorado, 80113
Englewood Hospital and Medical Center
Englewood, New Jersey, 07631
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Main Line Health Center-Exton
Exton, Pennsylvania, 19341
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Essentia Health Cancer Center-South University Clinic
Fargo, North Dakota, 58103
Sanford South University Medical Center
Fargo, North Dakota, 58103
Southpointe-Sanford Medical Center Fargo
Fargo, North Dakota, 58103
Sanford Medical Center Fargo
Fargo, North Dakota, 58104
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Armes Family Cancer Center
Findlay, Ohio, 45840
Blanchard Valley Hospital
Findlay, Ohio, 45840
Orion Cancer Care
Findlay, Ohio, 45840
Augusta Health Center for Cancer and Blood Disorders
Fishersville, Virginia, 22939
Cancer Hematology Centers - Flint
Flint, Michigan, 48503
Genesee Hematology Oncology PC
Flint, Michigan, 48503
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Kaiser Permanente-Fontana
Fontana, California, 92335
McFarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa, 50501
UI Healthcare Mission Cancer and Blood - Fort Dodge
Fort Dodge, Iowa, 50501
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Mercy Hospital Fort Smith
Fort Smith, Arkansas, 72903
Essentia Health - Fosston
Fosston, Minnesota, 56542
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Dayton Physicians LLC-Atrium
Franklin, Ohio, 45005
Ascension Saint Francis - Reiman Cancer Center
Franklin, Wisconsin, 53132
CentraState Medical Center
Freehold, New Jersey, 07728
Kaiser Permanente-Fremont
Fremont, California, 94538
Palo Alto Medical Foundation-Fremont
Fremont, California, 94538
Kaiser Permanente-Fresno
Fresno, California, 93720
Unity Hospital
Fridley, Minnesota, 55432
Gibbs Cancer Center-Gaffney
Gaffney, South Carolina, 29341
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
University of Texas Medical Branch
Galveston, Texas, 77555-0565
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
Aurora Health Care Germantown Health Center
Germantown, Wisconsin, 53022
MultiCare Gig Harbor Medical Park
Gig Harbor, Washington, 98335
Arizona Center for Cancer Care - Gilbert
Gilbert, Arizona, 85297
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland, 21061
Addison Gilbert Hospital
Gloucester, Massachusetts, 01930
Peninsula Cancer Institute-Gloucester
Gloucester, Virginia, 23061
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan, 49503
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan, 49503
Benefis Sletten Cancer Institute
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
Banner North Colorado Medical Center
Greeley, Colorado, 80631
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
East Carolina University
Greenville, North Carolina, 27834
Dayton Physicians LLC-Wayne
Greenville, Ohio, 45331
Wayne Hospital
Greenville, Ohio, 45331
Prisma Health Cancer Institute - Butternut
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Faris
Greenville, South Carolina, 29605
Prisma Health Greenville Memorial Hospital
Greenville, South Carolina, 29605
Prisma Health Cancer Institute - Eastside
Greenville, South Carolina, 29615
Prisma Health Cancer Institute - Greer
Greer, South Carolina, 29650
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Kaiser Permanente South Bay
Harbor City, California, 90710
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Advocate South Suburban Hospital
Hazel Crest, Illinois, 60429
OptumCare Cancer Care at Seven Hills
Henderson, Nevada, 89052
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
AdventHealth Hendersonville
Hendersonville, North Carolina, 28792
Essentia Health Hibbing Clinic
Hibbing, Minnesota, 55746
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii, 96819
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Kaiser Permanente-Irvine
Irvine, California, 92618
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, 28546
Essentia Health - Jamestown Clinic
Jamestown, North Dakota, 58401
McFarland Clinic - Jefferson
Jefferson, Iowa, 50129
MU Health Care Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Freeman Health System
Joplin, Missouri, 64804
Mercy Hospital Joplin
Joplin, Missouri, 64804
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Beacon Kalamazoo Cancer Center
Kalamazoo, Michigan, 49009
Logan Health Medical Center
Kalispell, Montana, 59901
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Greater Dayton Cancer Center
Kettering, Ohio, 45409
Kettering Medical Center
Kettering, Ohio, 45429
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Ballad Health Cancer Care - Kingsport
Kingsport, Tennessee, 37660
Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee, 37660
Marshfield Medical Center - Ladysmith
Ladysmith, Wisconsin, 54848
Kaiser Permanente-Rock Creek
Lafayette, Colorado, 80026
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Doctor's Hospital of Laredo
Laredo, Texas, 78041
OptumCare Cancer Care at Charleston
Las Vegas, Nevada, 89102
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
OptumCare Cancer Care at MountainView
Las Vegas, Nevada, 89128
OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada, 89148
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
UTMB Cancer Center at Victory Lakes
League City, Texas, 77573
Saint Joseph Radiation Oncology Resource Center
Lexington, Kentucky, 40504
Saint Joseph Hospital East
Lexington, Kentucky, 40509
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
AMG Libertyville - Oncology
Libertyville, Illinois, 60048
Condell Memorial Hospital
Libertyville, Illinois, 60048
CaroMont Health - Lincoln Cancer Center
Lincolnton, North Carolina, 28092
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Hope Cancer Clinic
Livonia, Michigan, 48154
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Kaiser Permanente-Lone Tree
Lone Tree, Colorado, 80124
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Kaiser Permanente West Los Angeles
Los Angeles, California, 90034
Banner McKee Medical Center
Loveland, Colorado, 80539
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, 53718
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143
McFarland Clinic - Marshalltown
Marshalltown, Iowa, 50158
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Fremont - Rideout Cancer Center
Marysville, California, 95901
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
Redeemer Health
Meadowbrook, Pennsylvania, 19046
Bon Secours Memorial Regional Medical Center
Mechanicsville, Virginia, 23116
Aspirus Medford Hospital
Medford, Wisconsin, 54451
Riddle Memorial Hospital
Media, Pennsylvania, 19063
Summa Health Medina Medical Center
Medina, Ohio, 44256
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, 53051
Ascension Columbia Saint Mary's Hospital Ozaukee
Mequon, Wisconsin, 53097
Idaho Urologic Institute-Meridian
Meridian, Idaho, 83642
Bon Secours Saint Francis Medical Center
Midlothian, Virginia, 23114
Beebe South Coastal Health Campus
Millville, Delaware, 19967
Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin, 53209
Ascension Columbia Saint Mary's Hospital - Milwaukee
Milwaukee, Wisconsin, 53211
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
About this study
Official title: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Read the detailed description
PRIMARY OBJECTIVES:
- Compare endocrine therapy (ET) adherence at 12 months in diverse women exposed to text message reminders (TMR)-only, telephone-based motivational interviewing counseling (MI)-only, or both (TMR+MI), versus usual care.
SECONDARY OBJECTIVES:
- Compare endocrine therapy (ET) adherence at 24 months in diverse women exposed to text message reminders (TMR)-only, telephone-based motivational interviewing counseling (MI)-only, or both (TMR+MI), versus usual care.
OUTLINE: Patients are randomized to 1 of 4 arms.
ARM I (TMR): Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.
ARM II (MI): Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.
ARM III (TMR + MI): Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.
ARM IV (ENHANCED USUAL CARE): Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.
After completion of study participation, patients are followed up for up to 24 months.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma
- Being tested
- Educational Intervention, Text Message-based Navigation Intervention, Motivational Interviewing, Best Practice, Questionnaire Administration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Educational InterventionOther
Receive online educational information about ET medication
Text Message-based Navigation InterventionOther
Receive text messages
Motivational InterviewingBehavioural
Receive motivational interviewing counseling sessions
Best PracticeOther
Also called Standard of Care
Attend usual care clinic visits
Questionnaire AdministrationOther
Ancillary studies
Quality-of-Life AssessmentOther
Ancillary studies
| Study group | Role | What they receive |
|---|---|---|
| Arm I (TMR) | Experimental | Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months. Receives: Other: Educational Intervention; Other: Text Message-based Navigation Intervention; Other: Questionnaire Administration; Other: Quality-of-Life Assessment |
| Arm II (MI) | Experimental | Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals. Receives: Other: Educational Intervention; Behavioral: Motivational Interviewing; Other: Questionnaire Administration; Other: Quality-of-Life Assessment |
| Arm III (TMR + MI) | Experimental | Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II. Receives: Other: Educational Intervention; Other: Text Message-based Navigation Intervention; Behavioral: Motivational Interviewing; Other: Questionnaire Administration; Other: Quality-of-Life Assessment |
| Arm IV (enhanced usual care) | Active comparator | Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer. Receives: Other: Educational Intervention; Other: Best Practice; Other: Questionnaire Administration; Other: Quality-of-Life Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Endocrine therapy (ET) adherence at 12 months post-randomization
ET adherence at 12 months post-randomization will be measured by electronic pill monitoring cap (AdhereTech-reported) and defined as the proportion of patients within each arm who have taken their ET medication for at least 292 of 365 days.
Measured: At 12 months post-randomization
Secondary outcomes (1)
Endocrine therapy (ET) adherence at 24 months post-randomization
ET adherence at 24 months post-randomization will be measured by electronic pill monitoring cap (Pillsy-reported) and defined as the proportion of patients within each arm who have taken their ET medication for at least 584 of 730 days.
Measured: At 24 months post-randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2020
- Study start15 Feb 2021
- Primary completion4 Oct 2026
- Study completion4 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Anatomic Stage I Breast Cancer AJCC v8Studies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,167 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Katherine E. Reeder-Hayes, MD, Study chair, University of North Carolina, Chapel Hill
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04379570
- Sponsor's protocol ID
- A191901
- Other IDs
- NCI-2020-02479, UG1CA189823, R01CA237357
- Status last verified
- Oct 2026
- First submitted
- 5 May 2020
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Ivory J, Wheeler SB, Drier S, Gunn H, Zahrieh D, Paskett E, Naughton M, Wills R, Swetel K, Chow S, Reeder-Hayes K. Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol. Trials. 2023 Oct 12;24(1):664. doi: 10.1186/s13063-023-07672-8.
PubMed 37828596
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
- ClinicalTrials.gov ID
- NCT04379570
- Acronym / sponsor ID
- A191901
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,167 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 15 Feb 2021 (actual)
- Primary completion
- 4 Oct 2026 (actual)
- Study completion
- 4 Oct 2027 (estimated)
- First posted
- 7 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Detailed description
PRIMARY OBJECTIVES:
- Compare endocrine therapy (ET) adherence at 12 months in diverse women exposed to text message reminders (TMR)-only, telephone-based motivational interviewing counseling (MI)-only, or both (TMR+MI), versus usual care.
SECONDARY OBJECTIVES:
- Compare endocrine therapy (ET) adherence at 24 months in diverse women exposed to text message reminders (TMR)-only, telephone-based motivational interviewing counseling (MI)-only, or both (TMR+MI), versus usual care.
OUTLINE: Patients are randomized to 1 of 4 arms.
ARM I (TMR): Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.
ARM II (MI): Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.
ARM III (TMR + MI): Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.
ARM IV (ENHANCED USUAL CARE): Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.
After completion of study participation, patients are followed up for up to 24 months.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Arm I (TMR) | Experimental | Other: Educational Intervention, Other: Text Message-based Navigation Intervention, Other: Questionnaire Administration, Other: Quality-of-Life AssessmentPatients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months. |
| Arm II (MI) | Experimental | Other: Educational Intervention, Behavioral: Motivational Interviewing, Other: Questionnaire Administration, Other: Quality-of-Life AssessmentPatients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals. |
| Arm III (TMR + MI) | Experimental | Other: Educational Intervention, Other: Text Message-based Navigation Intervention, Behavioral: Motivational Interviewing, Other: Questionnaire Administration, Other: Quality-of-Life AssessmentPatients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II. |
| Arm IV (enhanced usual care) | Active comparator | Other: Educational Intervention, Other: Best Practice, Other: Questionnaire Administration, Other: Quality-of-Life AssessmentPatients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Educational InterventionReceive online educational information about ET medication | Other | Arm I (TMR), Arm II (MI), Arm III (TMR + MI), Arm IV (enhanced usual care) |
| Text Message-based Navigation InterventionReceive text messages | Other | Arm I (TMR), Arm III (TMR + MI) |
| Motivational InterviewingReceive motivational interviewing counseling sessions | Behavioural | Arm II (MI), Arm III (TMR + MI) |
| Best PracticeAlso: Standard of CareAttend usual care clinic visits | Other | Arm IV (enhanced usual care) |
| Questionnaire AdministrationAncillary studies | Other | Arm I (TMR), Arm II (MI), Arm III (TMR + MI), Arm IV (enhanced usual care) |
| Quality-of-Life AssessmentAncillary studies | Other | Arm I (TMR), Arm II (MI), Arm III (TMR + MI), Arm IV (enhanced usual care) |
Primary outcome
Endocrine therapy (ET) adherence at 12 months post-randomization
Time frame: At 12 months post-randomization
ET adherence at 12 months post-randomization will be measured by electronic pill monitoring cap (AdhereTech-reported) and defined as the proportion of patients within each arm who have taken their ET medication for at least 292 of 365 days.
1 secondary outcome
Endocrine therapy (ET) adherence at 24 months post-randomization
Time frame: At 24 months post-randomization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Derived from this study: PubMed 37828596Ivory J, Wheeler SB, Drier S, Gunn H, Zahrieh D, Paskett E, Naughton M, Wills R, Swetel K, Chow S, Reeder-Hayes K. Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol. Trials. 2023 Oct 12;24(1):664. doi: 10.1186/s13063-023-07672-8.
- Individual participant dataSharing planned: Yes
Related trials for Anatomic Stage I Breast Cancer AJCC v8
Active, not recruitingPhase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Breast Carcinoma In Situ, Invasive Breast Carcinoma
Recruiting
A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
RecruitingPhase 3
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Not yet recruitingPhase 2
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Recruiting
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katherine E. Reeder-Hayes, MD study chair
University of North Carolina, Chapel Hill
526 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Educational Intervention, Text Message-based Navigation Intervention and Motivational Interviewing in people with Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, run by Alliance for Clinical Trials in Oncology at 526 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 526 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Endocrine therapy (ET) adherence at 12 months post-randomization (time frame: At 12 months post-randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04379570, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.